论文部分内容阅读
目的研究尿细胞角蛋白CYFRA 2l-1在膀胱癌中的表达。方法选择我院2011年12月至2012年5月32例经病理确诊的膀胱癌作为观察组,32例膀胱良性病变患者作为良性组,同时选择同期健康体检者32例为对照组,均取晨尿,对3组CYFRA 21-l进行检测,对CYFRA 21-l表达进行研究,同时对观察组患者不同病理分期、治疗前后CYFRA2l-1变化情况进行观察。结果观察组为(29.52±18.33)ng/ml,良性组为(4.47±2.33)ng/ml,观察组CYFRA21-1大大高于良性组与对照组,对照组CY-FRA21-1高于正常组,组间比较差异具有显著性,有统计学意义(P<0.05),浅表性膀胱癌CYFRA21-1检测值为(8.49±2.21)ng/ml,大大低于浸润性膀胱癌,两组比较差异具有显著性,有统计学意义(P<0.05),经手术、膀胱灌洗、放疗、化疗等治疗后,浅表性膀胱癌组CYFRA21-1下降明显,接近临界值,与治疗前比较差异具有显著性,有统计学意义(P<0.05),浸润性膀胱癌患者治疗后较治疗前略有下降,但下降幅度不大。结论尿CYFRA 2l-l检测对膀胱癌的诊断及预后判定均有较高的临床价值。
Objective To study the expression of urinary cytokeratin CYFRA 2l-1 in bladder cancer. Methods 32 cases of pathologically confirmed bladder cancer from December 2011 to May 2012 in our hospital were selected as the observation group and 32 cases of benign cystic benign disease were selected as the benign group. Meanwhile, 32 healthy subjects were selected as the control group, taking the morning Urine. CYFRA 21-l was detected in 3 groups. The expression of CYFRA 21-l was studied. The changes of CYFRA2l-1 in different groups were observed before and after the treatment. Results The positive rate of CYFRA21-1 in the observation group was (29.52 ± 18.33) ng / ml and (4.47 ± 2.33) ng / ml in the benign group, and that in the control group was significantly higher than that in the benign group and the control group (P <0.05). The detection value of CYFRA21-1 in superficial bladder cancer was (8.49 ± 2.21) ng / ml, which was much lower than that of invasive bladder cancer. There was significant difference between the two groups (P <0.05). After operation, bladder lavage, radiotherapy and chemotherapy, the expression of CYFRA21-1 in superficial bladder cancer group decreased significantly and approached the critical value, which was significantly lower than that before treatment Significantly, with statistical significance (P <0.05), invasive bladder cancer patients after treatment decreased slightly compared with before treatment, but the decline was not significant. Conclusion Urine CYFRA 2l-1 detection of bladder cancer diagnosis and prognosis have high clinical value.